Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
Condition(s):SchizophreniaLast Updated:September 29, 2023Not yet recruiting
Hide Studies Not Open or Pending
Condition(s):SchizophreniaLast Updated:September 29, 2023Not yet recruiting
Condition(s):Stimulant Use; MDMA (‘Ecstasy’); Social Behavior; MotivationLast Updated:January 24, 2024Completed
Condition(s):Social Avoidant Behavior; Major Depressive Disorder; Social Anxiety DisorderLast Updated:February 23, 2024Not yet recruiting
Condition(s):Autism Spectrum DisorderLast Updated:January 8, 2021Completed
Condition(s):Schizophrenia; Schizoaffective DisorderLast Updated:August 10, 2021Completed
Condition(s):Physical InactivityLast Updated:March 12, 2024Recruiting
Condition(s):LonelinessLast Updated:July 12, 2023Recruiting
Condition(s):Autism Spectrum DisordersLast Updated:June 18, 2021Completed
Condition(s):Autism; Autism Spectrum Disorder; Autistic Disorder; Asperger Syndrome; Pervasive Developmental DisorderLast Updated:August 31, 2023Completed
Condition(s):Type 1 DiabetesLast Updated:July 24, 2020Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.